The nation of Zimbabwe has rejected a major US health deal valued at $367m (272 million pounds) spanning five years over Washington's insistence on sensitive biological samples.
The decision came to light following a government memo from December was leaked, indicating that Head of State Emmerson Mnangagwa believed the deal was "unbalanced".
A government spokesperson has since clarified that the United States was demanding access to health data for research and commercial gain while was unwilling to guarantee the resulting advantages from future treatments.
"We will now turn to the challenging and unfortunate task of ending our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had provided over $1.9bn for health programmes to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for further negotiations to secure a deal suitable to all parties so the country's critical HIV programme can continue.
Wider Implications
This development comes after a comparable situation in Kenya, where a high court blocked a similar deal with the US after concerns were filed about the security of citizens' medical information.
After resuming office recently, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
USAID had managed assistance for the US government, but Trump stated its expenditure was "wasteful" and his administration was seeking government-to-government agreements to boost transparency and accountability.
As per reports, Sixteen nations in Africa have to date signed these new agreements, constituting more than $18.3bn in committed funds.
Specifics of the Declined Deal
The money for Zimbabwe was intended to supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this cooperation might have yielded immense advantages for Zimbabwean communities, especially the 1.2 million currently receiving antiretroviral therapy through US-supported initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to provide its biological resources and data over an extended period, without any corresponding promise of benefiting from any medical innovations – such as new medicines or tests – that could result from that shared data," he stated.
"Effectively, our country would provide the raw materials for scientific discovery without any assurance that the end products would be accessible to our citizens if a future disease outbreak emerge."
National Interest and Global Health
Mangwana further said that the US's withdrawal from the global health body and its pursuit of one-on-one deals were upending structures previously set up through the international health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework designed to manage potential pandemics.
"This system is designed to guarantee that when a nation provides its information, the resulting advantages – such as vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the funds to develop them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We are open to continued dialogue with our US partners on how subsequent co-operation could be arranged in a manner that honours the independence and interests of both nations."
Medical Community Reaction
Medical experts stated it acknowledged the government's concerns, but suggested that talks must proceed considering a large portion of the nation's HIV programmes depended on international support.
"If technical issues exist, including those relating to data governance or agreement terms, these can frequently be resolved via detailed discussion and negotiated safeguards," it added.
The situation highlights the continuing tensions between receiving crucial foreign assistance and protecting a country's data in an increasingly data-driven world.